Anonymousabout 3 hours ago
President Trump signed an executive order on April 18, 2026 directing the FDA, DEA, and VA to accelerate access to psychedelic therapies including psilocybin, MDMA, and ibogaine, committing $50 million in ARPA-H funding and issuing unprecedented National Priority Vouchers for fast-track review. The move has energized veterans' groups and biotech investors but raised concerns from scientists who warn that political momentum may be outpacing clinical evidence, and from drug-policy reformers who argue that pharmaceutical medicalization will exclude the communities most harmed by the War on Drugs.